Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Astellas Pharma Inc.
Sort By
Newest First
1 / 1
1 / 1
M&A
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
Astellas
PR-M01-20-NI-006
Jan 03, 2020
Patient Centricity
Astellas Takes Patient Centricity to the Next Level
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M09-19-NI-019
Sep 20, 2019
License Agreement
Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss
Astellas
PR-M07-19-NI-055
Jul 22, 2019
BLA
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin
Astellas
PR-M07-19-NI-050
Jul 19, 2019
Collaboration
Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated
Actinium Pharmaceuticals, Inc.
PR-M04-19-NI-011
Apr 03, 2019
Collaboration
Actinium Pharma and Astellas Move to Third Phase of Their Collaboration
Nice Insight
PAO-M04-19-NI-006
Apr 02, 2019
Launch
Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients
Astellas
PR-M03-19-NI-051
Mar 19, 2019
Collaboration
Astellas and WiserCare Announce Collaboration to Improve Patient Experience
Astellas
PR-M02-19-NI-057
Feb 26, 2019
Launch
Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Astellas
PR-M12-18-NI-057
Dec 17, 2018
Leukemia
Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Astellas
PR-M12-18-NI-025
Dec 07, 2018
Launch
Astellas Global Health Foundation Launches
Astellas
PR-M11-18-NI-087-3340
Nov 26, 2018
Acquisition
Quethera Acquired by Astellas Pharma
Emilie Branch
Pharma's Almanac
PAO-M08-18-NI-018
Aug 14, 2018
FDA Approval
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
Astellas
PR-M07-18-NI-047
Jul 16, 2018
Appointment
Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas
Astellas
PR-M06-18-NI-031
Jun 11, 2018
Radio-Conjugates
Companies Join Forces to Develop Novel Radio-Conjugates
Nigel Walker
Nice Insight
PAO-M04-18-NI-002
Apr 04, 2018
Strategic Partnership
Mitochondrial Expert Mitobridge Snapped Up by Astellas Pharma
Nice Insight
PAO-M01-18-NI-002
Jan 02, 2018
Acquisition
Astellas Completes Acquisition of Ogeda
Guy Tiene
Nice Insight
PAO-M05-17-NI-026
May 23, 2017
